BerGenBio has delivered solid clinical efficacy data in 2019
Next step is to harvest on the results and start pivotal studies
The Axl-antibody, tilvestamab, will also advance this year
Updated data in Q2/20 and design of pivotal studies are next triggers

11 Feb 2020
2020 will be an eventful year for BerGenBio

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2020 will be an eventful year for BerGenBio
BerGenBio has delivered solid clinical efficacy data in 2019
Next step is to harvest on the results and start pivotal studies
The Axl-antibody, tilvestamab, will also advance this year
Updated data in Q2/20 and design of pivotal studies are next triggers